Ensembles of protein termini and specific proteolytic signatures as candidate biomarkers of disease

Proteomics - Clinical Applications

Volumn 8, Issue 5-6, 2014, Pages 338-350

  Huesgen, Pitter F ^a   Lange, Philipp F ^a   Overall, Christopher M ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Biomarker; Neo peptides; Neoepitope antibody; Posttranslational modification; Protein termini; Proteolysis

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-42]; AMYLOID PRECURSOR PROTEIN; BETA SECRETASE; BIOLOGICAL MARKER; EPITOPE; FIBRIN; FIBRINOGEN; GLYCOSYLATED HEMOGLOBIN; PROTEIN; PROTEOME; TAU PROTEIN;

ALZHEIMER DISEASE; AMINO TERMINAL SEQUENCE; ANALYTIC METHOD; CARBOXY TERMINAL AMINE BASED ISOTOPE LABELING OF SUBSTRATE; CARBOXY TERMINAL SEQUENCE; DISEASE MARKER; HUMAN; ISOTOPE LABELING; MALIGNANT NEOPLASTIC DISEASE; NEUROPATHOLOGY; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN CLEAVAGE; PROTEIN DEGRADATION; PROTEIN DETERMINATION; PROTEIN DOMAIN; PROTEIN FUNCTION; PROTEIN PROCESSING; PROTEOMICS; REVIEW; TERMINAL AMINE ISOTOPE LABELING OF SUBSTRATE; UNINDEXED SEQUENCE; ANIMAL; CHEMISTRY; DISEASES; METABOLISM; PROCEDURES;

ANIMALS; BIOLOGICAL MARKERS; DISEASE; HUMANS; PROTEIN PROCESSING, POST-TRANSLATIONAL; PROTEINS; PROTEOLYSIS; PROTEOMICS;

EID: 84902082685     PISSN: 18628346     EISSN: 18628354     Source Type: Journal    
DOI: 10.1002/prca.201300104     Document Type: Review

References (83)

1. Seo, D., Ginsburg, G. S., Genomic medicine: bringing biomarkers to clinical medicine. Curr. Opin. Chem. Biol. 2005, 9, 381-386.
2. Rifai, N., Gillette, M. A., Carr, S. A., Protein biomarker discovery and validation: the long and uncertain path to clinical utility. Nat. Biotechnol. 2006, 24, 971-983.
3. Hamburg, M. A., Collins, F. S., The path to personalized medicine. N. Engl. J Med. 2010, 363, 301-304.
4. Diamond, D. L., Krasnoselsky, A. L., Burnum, K. E., Monroe, M. E. et al., Proteome and computational analyses reveal new insights into the mechanisms of hepatitis C virus-mediated liver disease posttransplantation. Hepatology 2012, 56, 28-38.
5. Butko, M. T., Savas, J. N., Friedman, B., Delahunty, C. et al., In vivo quantitative proteomics of somatosensory cortical synapses shows which protein levels are modulated by sensory deprivation. Proc. Natl. Acad. Sci. 2013, 110, E726-E735.
6. Geiger, T., Madden, S. F., Gallagher, W. M., Cox, J., Mann, M., Proteomic portrait of human breast cancer progression identifies novel prognostic markers. Cancer Res. 2012, 72, 2428-2439.
7. Auf dem Keller, U., Prudova, A., Eckhard, U., Fingleton, B., Overall, C. M., Systems-level analysis of proteolytic events in increased vascular permeability and complement activation in skin inflammation. Sci. Signal. 2013, 6, rs2.
8. Parker, C. E., Pearson, T. W., Anderson, N. L., Borchers, C. H., Mass-spectrometry-based clinical proteomics-a review and prospective. Analyst 2010, 135, 1830-1838.
9. Anderson, N. L., Ptolemy, A. S., Rifai, N., The riddle of protein diagnostics: future bleak or bright? Clin. Chem. 2013, 59, 194-197.
10. Gillette, M. A., Carr, S. A., Quantitative analysis of peptides and proteins in biomedicine by targeted mass spectrometry. Nat. Methods 2013, 10, 28-34.
11. Taguchi, A., Hanash, S. M., Unleashing the power of proteomics to develop blood-based cancer markers. Clin. Chem. 2013, 59, 119-126.
12. Cohen Freue, G. V., Meredith, A., Smith, D., Bergman, A. et al., Computational biomarker pipeline from discovery to clinical implementation: plasma proteomic biomarkers for cardiac transplantation. PLoS Comput. Biol. 2013, 9, e1002963.
13. Jensen, O. N., Interpreting the protein language using proteomics. Nat. Rev. Mol. Cell Biol. 2006, 7, 391-403.
14. Lange, P. F., Overall, C. M., Protein TAILS: when termini tell tales of proteolysis and function. Curr. Opin. Chem. Biol. 2013, 17, 73-82.
15. Krueger, K. E., Srivastava, S., Posttranslational protein modifications current implications for cancer detection, prevention, and therapeutics. Mol. Cell. Proteomics 2006, 5, 1799-1810.
16. Kitteringham, N. R., Jenkins, R. E., Lane, C. S., Elliott, V. L., Park, B. K., Multiple reaction monitoring for quantitative biomarker analysis in proteomics and metabolomics. J. Chromatogr. B 2009, 877, 1229-1239.
17. López-Otín, C., Bond, J. S., Proteases: multifunctional enzymes in life and disease. J. Biol. Chem. 2008, 283, 30433-30437.
18. Dufour, A., Overall, C. M., Missing the target: matrix metalloproteinase antitargets in inflammation and cancer. Trends Pharmacol. Sci. 2013, 34, 233-242.
19. Turk, B., Turk, D., Turk, V., Protease signalling: the cutting edge. EMBO J. 2012, 31, 1630-1643.
20. O'Brien, R. J., Wong, P. C., Amyloid precursor protein processing and Alzheimer's disease. Annu. Rev. Neurosci. 2011, 34, 185-204.
21. De Strooper, B., Annaert, W., Novel research horizons for presenilins and γ-secretases in cell biology and disease. Annu. Rev. Cell. Dev. Biol. 2010, 26, 235-260.
22. Motter, R., Vigo-Pelfrey, C., Kholodenko, D., Barbour, R. et al., Reduction of beta-amyloid peptide42 in the cerebrospinal fluid of patients with Alzheimer's disease. Ann. Neurol. 1995, 38, 643-648.
23. Vanderstichele, H., Blennow, K., D'Heuvaert, N., Buyse, M.-A. et al., Development of a specific diagnostic test for measurement of β-amyloid (1-42)[βA4 (l-42)] in CSF. Adv. Behavioral Biol. 1998, 49, 773-778.
24. Kang, J. H., Korecka, M., Toledo, J. B., Trojanowski, J. Q., Shaw, L. M., Clinical utility and analytical challenges in measurement of cerebrospinal fluid amyloid- 1-42 and proteins as Alzheimer disease biomarkers. Clin. Chem. 2013, 59, 903-916.
25. Wu, G., Sankaranarayanan, S., Wong, J., Tugusheva, K. et al., Characterization of plasma β-secretase (BACE1) activity and soluble amyloid precursor proteins as potential biomarkers for Alzheimer's disease. J. Neurosci. Res. 2012, 90, 2247-2258.
26. Mattsson, N., Rosen, E., Hansson, O., Andreasen, N. et al., Age and diagnostic performance of Alzheimer disease CSF biomarkers. Neurology 2012, 78, 468-476.
27. Cox, J. H., Overall, C. M., Edwards, D., Hoyer-Hansen, G., Blasi, F., Sloane, B. F. (Eds), The cancer degradome. Springer, New York 2008, pp. 519-539.
28. McQuibban, G. A., Inflammation dampened by gelatinase A cleavage of monocyte chemoattractant protein-3. Science 2000, 289, 1202-1206.
29. Zhang, K., McQuibban, G. A., Silva, C., Butler, G. S. et al., HIV-induced metalloproteinase processing of the chemokine stromal cell derived factor-1 causes neurodegeneration. Nat. Neurosci. 2003, 6, 1064-1071.
30. Anderson, N. L., The clinical plasma proteome: a survey of clinical assays for proteins in plasma and serum. Clin. Chem. 2010, 56, 177-185.
31. McCulloch, P., Nieuwenhuizen, W., Douglas, J., Lowe, G. D. O., George, W. D., Coagulation disturbances in cancer of the breast and colon measured with specific monoclonal antibody enzyme immunoassay for fibrin-fibrinogen degradation products. Pathophysiol. Haemos. Thromb. 1990, 20, 73-80.
32. Lange, P. F., Overall, C. M., TopFIND, a knowledgebase linking protein termini with function. Nat. Methods 2011, 8, 703-704.
33. Lange, P. F., Huesgen, P. F., Nguyen, K., Overall, C. M., Annotating N termini for the Human Proteome Project: N termini and Nα-acetylation status differentiate stable cleaved protein species from degradation remnants in the human erythrocyte proteome. J. Proteome Res. 2014. in press.
34. Marchant, D. J., Bellac, C., Moraes, T. J., Wadsworth, S. J. et al., Transcriptional role of moonlightning MMP12 in antiviral Immunity. Nat. Medicine 2014, in press.
35. Meinnel, T., Giglione, C., Tools for analyzing and predicting N-terminal protein modifications. Proteomics 2008, 8, 626-649.
36. Varshavsky, A., The N-end rule pathway and regulation by proteolysis. Protein Sci. 2011, 20, 1298-1345.
37. Bunn, H. F., Nonenzymatic glycosylation of proterelevance to diabetes. Am. J. Med. 1981, 70, 325-330.
38. Larsen, M. L., Hørder, M., Mogensen, E. F., Effect of long-term monitoring of glycosylated hemoglobin levels in insulin-dependent diabetes mellitus. N. Engl. J. Med. 1990, 323, 1021-1025.
39. Saido, T. C., Iwatsubo, T., Mann, D., Shimada, H. et al., Dominant and differential deposition of distinct β-amyloid peptide species, A β N3 (pE), in senile plaques. Neuron 1995, 14, 457-466.
40. Näslund, J., Schierhorn, A., Hellman, U., Lannfelt, L. et al., Relative abundance of Alzheimer A beta amyloid peptide variants in Alzheimer disease and normal aging. Proc. Natl. Acad. Sci. USA 1994, 91, 8378-8382.
41. Liu, K., Solano, I., Mann, D., Lemere, C. et al., Characterization of Aβ11-40/42 peptide deposition in Alzheimer's disease and young Down's syndrome brains: implication of N-terminally truncated Aβ species in the pathogenesis of Alzheimer's disease. Acta. Neuropathol. 2006, 112, 163-174.
42. Bien, J., Jefferson, T., Čaušević, M., Jumpertz, T. et al., The metalloprotease meprin β generates amino terminal-truncated amyloid β peptide species. J. Biol. Chem. 2012, 287, 33304-33313.
43. Schilling, S., Zeitschel, U., Hoffmann, T., Heiser, U. et al., Glutaminyl cyclase inhibition attenuates pyroglutamate Aβ and Alzheimer's disease-like pathology. Nat. Med. 2008, 14, 1106-1111.
44. Saido, T. C., Alzheimer's disease as proteolytic disorders: anabolism and catabolism of beta-amyloid. Neurobiol. Aging 1998, 19, S69-S75.
45. Schilling, S., Lauber, T., Schaupp, M., Manhart, S. et al., On the seeding and oligomerization of pGlu-amyloid peptides (in vitro). Biochemistry 2006, 45, 12393-12399.
46. Lange, P. F., Huesgen, P. F., Overall, C. M., TopFIND 2.0 - linking protein termini with proteolytic processing and modifications altering protein function. Nucl. Acids Res. 2012, 40, D351-D361.
47. Latterich, M., Schnitzer, J. E., Streamlining biomarker discovery. Nat. Biotechnol. 2011, 29, 600-602.
48. Phillips, K. A., Van Bebber, S., Issa, A. M., Diagnostics and biomarker development: priming the pipeline. Nat. Rev. Drug Discov. 2006, 5, 463-469.
49. Huesgen, P. F., Overall, C. M., N- and C-terminal degradomics: new approaches to reveal biological roles for plant proteases from substrate identification. Physiol. Plant 2012, 145, 5-17.
50. Rogers, L. D., Overal, C. M., Proteolytic post-translational modification of proteins: Proteomic tools and methodology. Mol. Cell. Proteomics 2013, 12, 3532-3542.
51. Plasman, K., Van Damme, P., Gevaert, K., Contemporary positional proteomics strategies to study protein processing. Cell 2013, 17, 66-72.
52. Kleifeld, O., Doucet, A., Auf dem Keller, U., Prudova, A. et al., Isotopic labeling of terminal amines in complex samples identifies protein N-termini and protease cleavage products. Nat. Biotechnol. 2010, 28, 281-288.
53. Schilling, O., Barré, O., Huesgen, P. F., Overall, C. M., Proteome-wide analysis of protein carboxy termini: C terminomics. Nat. Methods 2010, 7, 508-511.
54. Gevaert, K., Goethals, M., Martens, L., Van Damme, J. et al., Exploring proteomes and analyzing protein processing by mass spectrometric identification of sorted N-terminal peptides. Nat. Biotechnol. 2003, 21, 566-569.
55. Wildes, D., Wells, J. A., Sampling the N-terminal proteome of human blood. Proc. Natl. Acad. Sci. 2010, 107, 4561-4566.
56. Borchers, C. H., Kast, J., Foster, L. J., Siu, K. W. M. et al., The Human Proteome Organization Chromosome 6 Consortium: integrating chromosome-centric and biology/disease driven strategies. J. Proteomics 2013. doi: 10.1016/j.jprot.2013.08.001. [Epub ahead of print]
57. Addona, T. A., Shi, X., Keshishian, H., Mani, D. R. et al., A pipeline that integrates the discovery and verification of plasma protein biomarkers reveals candidate markers for cardiovascular disease. Nat. Biotechnol. 2011, 29, 635-643.
58. Whiteaker, J. R., Lin, C., Kennedy, J., Hou, L. et al., A targeted proteomics-based pipeline for verification of biomarkers in plasma. Nat. Biotechnol. 2011, 29, 625-634.
59. Anderson, L., Hunter, C. L., Quantitative mass spectrometric multiple reaction monitoring assays for major plasma proteins. Mol. Cell. Proteomics 2006, 5, 573-588.
60. Lange, V., Picotti, P., Domon, B., Aebersold, R., Selected reaction monitoring for quantitative proteomics: a tutorial. Mol. Syst. Biol. 2008, 4, 222.
61. Fahlmann, R. P., Chen, W., Overall, C. M., Absolute proteomic quantification of the activity state of proteases and proteolytic cleavages using proteolytic signature peptides and isobaric tags. J. Proteomics 2013. doi: 10.1016/j.jprot.2013.09.006. [Epub ahead of print].
62. Addona, T. A., Abbatiello, S. E., Schilling, B., Skates, S. J. et al., Multi-site assessment of the precision and reproducibility of multiple reaction monitoring-based measurements of proteins in plasma. Nat. Biotechnol. 2009, 27, 633-641.
63. Abbatiello, S. E., Mani, D. R., Schilling, B., MacLean, B. et al., Design, implementation and multisite evaluation of a system suitability protocol for the quantitative assessment of instrument performance in liquid chromatography-multiple reaction monitoring-MS (LC-MRM-MS). Mol. Cell. Proteomics 2013, 12, 2623-2639.
64. Percy, A. J., Chambers, A. G., Yang, J., Jackson, A. M. et al., Method and platform standardization in MRM-based quantitative plasma proteomics. J. Proteomics 2013, 95, 66-76.
65. Starr, A. E., Overall, C. M., Chapter 13. Characterizing proteolytic processing of chemokines by mass spectrometry, biochemistry, neo-epitope antibodies and functional assays. Meth. Enzymol. 2009, 461, 281-307.
66. Hughes, C. E., Caterson, B., White, R. J., Roughley, P. J., Mort, J. S., Monoclonal antibodies recognizing protease-generated neoepitopes from cartilage proteoglycan degradation. Application to studies of human link protein cleavage by stromelysin. J. Biol. Chem. 1992, 267, 16011-16014.
67. Diamandis, E. P., Mass spectrometry as a diagnostic and a cancer biomarker discovery tool: opportunities and potential limitations. Mol. Cell. Proteomics 2004, 3, 367-378.
68. Gauci, S., Helbig, A. O., Slijper, M., Krijgsveld, J. et al., Lys-N and trypsin cover complementary parts of the phosphoproteome in a refined SCX-based approach. Anal. Chem. 2009, 81, 4493-4501.
69. Kleifeld, O., Doucet, A., Prudova, A., Keller, U. A. D. et al., Identifying and quantifying proteolytic events and the natural N terminome by terminal amine isotopic labeling of substrates. Nat. Protoc. 2011, 6, 1578-1611.
70. Burkhart, J. M., Schumbrutzki, C., Wortelkamp, S., Sickmann, A., Zahedi, R. P., Systematic and quantitative comparison of digest efficiency and specificity reveals the impact of trypsin quality on MS-based proteomics. J. Proteomics 2012, 75, 1454-1462.
71. Proc, J. L., Kuzyk, M. A., Hardie, D. B., Yang, J. et al., A quantitative study of the effects of chaotropic agents, surfactants, and solvents on the digestion efficiency of human plasma proteins by trypsin. J. Proteome Res. 2010, 9, 5422-5437.
72. Shi, T., Su, D., Liu, T., Tang, K. et al., Advancing the sensitivity of selected reaction monitoring-based targeted quantitative proteomics. Proteomics 2012, 12, 1074-1092.
73. Villanueva, J., Shaffer, D. R., Philip, J., Chaparro, C. A. et al., Differential exoprotease activities confer tumor-specific serum peptidome patterns. J. Clin. Invest. 2006, 116, 271-284.
74. Kuhn, E., Addona, T., Keshishian, H., Burgess, M. et al., Developing multiplexed assays for troponin I and interleukin-33 in plasma by peptide immunoaffinity enrichment and targeted mass spectrometry. Clin. Chem. 2009, 55, 1108-1117.
75. Whiteaker, J. R., Zhao, L., Anderson, L., Paulovich, A. G., An automated and multiplexed method for high throughput peptide immunoaffinity enrichment and multiple reaction monitoring mass spectrometry-based quantification of protein biomarkers. Mol. Cell. Proteomics 2010, 9, 184-196.
76. Pepe, M. S., Feng, Z., Janes, H., Bossuyt, P. M., Potter, J. D., Pivotal evaluation of the accuracy of a biomarker used for classification or prediction: standards for study design. J. Natl. Cancer Inst. 2008, 100, 1432-1438.
77. Paulovich, A. G., Whiteaker, J. R., Hoofnagle, A. N., Wang, P., The interface between biomarker discovery and clinical validation: the tar pit of the protein biomarker pipeline. Prot. Clin. Appl. 2008, 2, 1386-1402.
78. Sacks, D. B., Measurement of hemoglobin A1c A new twist on the path to harmony. Diabetes Care 2012, 35, 2674-2680.
79. Bates, S. M., Weitz, J. I., Coagulation assays. Circulation 2005, 112, e53-e60.
80. Campbell, D. J., Nussberger, J., Stowasser, M., Danser, A. H. J. et al., Activity assays and immunoassays for plasma Renin and proreninformation provided and precautions necessary for accurate measurement. Clin. Chem. 2009, 55, 867-877.
81. Kwong, G. A., Maltzahn von, G., Murugappan, G., Abudayyeh, O. et al., Mass-encoded synthetic biomarkers for multiplexed urinary monitoring of disease. Nat. Biotechnol. 2012, 31, 63-70.
82. Funk, D. M. A., Coagulation assays and anticoagulant monitoring. Hematology 2012, 2012, 460-465.
83. Edgington, L. E., Verdoes, M., Bogyo, M., Functional imaging of proteases: recent advances in the design and application of substrate-based and activity-based probes. Curr. Opin. Chem. Biol. 2011, 15, 798-805.